Skip to content
Tablet Allopathic

Dakla 60 mg tablet

Generic: Daclatasvir

Company: Healthcare Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength60 mg
PackBox of 7: 2800.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Daclatasvir 60 mg tablets

Prices as listed on BestinMeds.

2 brands listed
G-Daclatasvir200.00 taka per tablet
Dakla, box of 7 (this medicine)400.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Daclatasvir guide

Indications

Chronic hepatitis C Daclatasvir is indicated in combination with Sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Dosage and administration

Recommended Dosage: The recommended dose of Daclatasvir is 60 mg once daily, to be taken orally with or without meals. Daclatasvir must be administered in combination with other medicinal products. The Summary of Product Characteristics for the other medicinal products in the regimen should also be consulted before initiation of therapy with Daclatasvir. Recommended regimens and treatment duration are provided in table below: For the regimen of Daclatasvir+Sofosbuvir, data for 12-week treatment duration are available only for treatment-naïve patients with genotype 1 infection. For Daclatasvir+Sofosbuvir with or without Ribavirin, data are available for patients with advanced liver disease (≥F3) without cirrhosis. The recommended use of Daclatasvir+Sofosbuvir in genotype 4 is based on extrapolation from genotype 1. For the regimen of Daclatasvir+Peginterferon alfa + Ribavirin, data are available for treatment-naïve patients. The dose of Ribavirin, when combined with Daclatasvir, is weight-based (1,000 or 1,200 mg in patients

Side effects

The following serious adverse reactions are described below and elsewhere in the labeling: Serious Symptomatic Bradycardia When Coadministered with Sofosbuvir and Amiodarone. One can get any of the following symptoms: Fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, memory problems.

Precautions and warnings

Risk of adverse reactions or loss of virologic response due to drug interactions. The concomitant use of Daclatasvir and other drugs may result in known or potentially significant drug interactions, some of which may lead to: loss of therapeutic effect of Daclatasvir and possible development of resistance dosage adjustments of concomitant medications or Daclatasvir possible clinically significant adverse reactions from greater exposures of concomitant drugs or Daclatasvir Serious Symptomatic Bradycardia When Coadministered with Sofosbuvir and Amiodarone and patients counseling: Postmarketing cases of symptomatic bradycardia and cases requiring pacemaker intervention have been reported when Amiodarone is coadministered with Sofosbuvir in combination with another HCV direct-acting antiviral, including Daclatasvir. Patients who are taking Sofosbuvir in combination with Daclatasvir who need to start Amiodarone therapy due to no other alternative treatment options should undergo cardiac monitoring.

Pregnancy and lactation

No data with Daclatasvir in pregnant women are available to inform a drug-associated risk. No information regarding the presence of Daclatasvir in human milk, the effects on the breastfed infant, or the effects on milk production is available.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250